newsfilter
← Latest News
PR Newswire·

Eiger BioPharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update

Phase 3 HDV D-LIVR (lonafarnib-based regimens) Study Topline Data in DecemberPhase 3 HDV LIMT-2 (peginterferon lambda) Study Activating Sites and Enrolling PatientsPhase 3 Congenital Hyperinsulinism Avant (avexitide)